Abstract:
Conclusion According to our results, for HBe antigen-negative CHB cases, the response rate during the sixth month after the treatment with PegIFN was determined to be similar to 17%. No difference was found between the efficacy rates of the two PegIFN products used in the treatment of HBe antigen-negative CHB. Eur J Gastroenterol Hepatol 24: 1296-1301 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.